Palladium(II) and Platinum(II) Organometallic Complexes with the Model Nucleobase Anions of Thymine, Uracil, and Cytosine: Antitumor Activity and Interactions with DNA of the Platinum Compounds
详细信息 查看全文
- 作者：José ; Ruiz ; Julia Lorenzo ; Laura Sanglas ; Natalia Cutillas ; Consuelo Vicente ; Marí ; a Dolores Villa ; Francesc X. Avilé ; s ; Gregorio Ló ; pez ; Virtudes Moreno ; José ; Pé
- 刊名：Inorganic Chemistry
- 出版年：2006
- 出版时间：August 7, 2006
- 年：2006
- 卷：45
- 期：16
- 页码：6347 - 6360
- 全文大小：615K
- 年卷期：v.45,no.16(August 7, 2006)
- ISSN：1520-510X
文摘
Pd(II) and Pt(II) complexes with the anions of the model nucleobases 1-methylthymine (1-MethyH), 1-methyluracil(1-MeuraH), and 1-methylcytosine (1-MecytH) of the types [Pd(dmba)(
-L)]2 [dmba = N,C-chelating 2-((dimethylamino)methyl)phenyl; L = 1-Methy, 1-Meura or 1-Mecyt] and [M(dmba)(L)(L')] [L = 1-Methy or 1-Meura; L' =PPh3 (M = Pd or Pt), DMSO (M = Pt)] have been obtained. Palladium complexes of the types [Pd(C6F5)(N-N)(L)][L = 1-Methy or 1-Meura; N-N = N,N,N',N'-tetramethylethylenediamine (tmeda), 2,2'-bipyridine (bpy), or 4,4'-dimethyl-2,2'-bipyridine (Me2bpy)] and [NBu4][Pd(C6F5)(1-Methy)2(H2O)] have also been prepared. The crystalstructures of [Pd(dmba)(-1-Methy)]2, [Pd(dmba)(-1-Mecyt)]2·2CHCl3, [Pd(dmba)(1-Methy)(PPh3)]·3CHCl3, [Pt(dmba)(1-Methy)(PPh3)], [Pd(tmeda)(C6F5)(1-Methy)], and [NBu4][Pd(C6F5)(1-Methy)2(H2O)]·H2O have been established byX-ray diffraction. The DNA adduct formation of the new platinum complexes synthesized was followed by circulardichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the platinumcomplexes on plasmid DNA pBR322 were also obtained. Values of IC50 were also calculated for the new platinumcomplexes against the tumor cell line HL-60. All the new platinum complexes were more active than cisplatin (upto 20-fold in some cases).
-L)]2 [dmba = N,C-chelating 2-((dimethylamino)methyl)phenyl; L = 1-Methy, 1-Meura or 1-Mecyt] and [M(dmba)(L)(L')] [L = 1-Methy or 1-Meura; L' =PPh3 (M = Pd or Pt), DMSO (M = Pt)] have been obtained. Palladium complexes of the types [Pd(C6F5)(N-N)(L)][L = 1-Methy or 1-Meura; N-N = N,N,N',N'-tetramethylethylenediamine (tmeda), 2,2'-bipyridine (bpy), or 4,4'-dimethyl-2,2'-bipyridine (Me2bpy)] and [NBu4][Pd(C6F5)(1-Methy)2(H2O)] have also been prepared. The crystalstructures of [Pd(dmba)(-1-Methy)]2, [Pd(dmba)(-1-Mecyt)]2·2CHCl3, [Pd(dmba)(1-Methy)(PPh3)]·3CHCl3, [Pt(dmba)(1-Methy)(PPh3)], [Pd(tmeda)(C6F5)(1-Methy)], and [NBu4][Pd(C6F5)(1-Methy)2(H2O)]·H2O have been established byX-ray diffraction. The DNA adduct formation of the new platinum complexes synthesized was followed by circulardichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the platinumcomplexes on plasmid DNA pBR322 were also obtained. Values of IC50 were also calculated for the new platinumcomplexes against the tumor cell line HL-60. All the new platinum complexes were more active than cisplatin (upto 20-fold in some cases).